Betta Pharmaceuticals Co., Ltd. (SHE: 300558)
China
· Delayed Price · Currency is CNY 36.84
-0.50 (-1.34%)
Sep 9, 2024, 1:17 PM CST
Betta Pharmaceuticals Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 423.67 | 348.03 | 145.42 | 383.07 | 606.36 | 230.82 | Upgrade
|
| Depreciation & Amortization | 330.44 | 303.49 | 253.7 | 174.46 | 155.16 | 142.76 | Upgrade
|
| Other Amortization | - | - | - | - | 0.7 | 0.7 | Upgrade
|
| Loss (Gain) From Sale of Assets | 5.86 | 0.01 | -88.61 | -0.07 | 1.7 | -0.29 | Upgrade
|
| Asset Writedown & Restructuring Costs | 1.59 | 1.07 | 3.01 | 0.03 | 10.25 | 0.08 | Upgrade
|
| Loss (Gain) From Sale of Investments | 8.47 | 13.67 | 20.62 | -15.96 | -292.66 | 0.8 | Upgrade
|
| Provision & Write-off of Bad Debts | -3.64 | 5.43 | 1.44 | - | - | 0.36 | Upgrade
|
| Other Operating Activities | 35.56 | 37.19 | 166.66 | 16.53 | 43.01 | 41.75 | Upgrade
|
| Change in Accounts Receivable | 346.64 | 174.2 | -198.29 | -181.6 | -15.65 | -11.19 | Upgrade
|
| Change in Inventory | 34.85 | 44.67 | -78.85 | -104.73 | -55.36 | 12.12 | Upgrade
|
| Change in Accounts Payable | -124.57 | 14.71 | -9.1 | 205.07 | 141.27 | 112.7 | Upgrade
|
| Change in Other Net Operating Assets | -3.47 | -16.46 | 132.53 | 75.97 | 62.53 | 45.12 | Upgrade
|
| Operating Cash Flow | 1,076 | 914.23 | 306.74 | 526.63 | 646.02 | 555.07 | Upgrade
|
| Operating Cash Flow Growth | 99.48% | 198.05% | -41.75% | -18.48% | 16.38% | 93.81% | Upgrade
|
| Capital Expenditures | -911.49 | -1,096 | -1,011 | -758.38 | -685.84 | -620.42 | Upgrade
|
| Sale of Property, Plant & Equipment | -0.27 | 22.21 | 0.69 | 0.24 | 1.55 | 0.39 | Upgrade
|
| Cash Acquisitions | - | - | - | -190.36 | - | -17.3 | Upgrade
|
| Divestitures | - | - | - | - | 259.75 | - | Upgrade
|
| Investment in Securities | -345.57 | -431.65 | -314.49 | -33.62 | -328.87 | -31.55 | Upgrade
|
| Other Investing Activities | - | - | - | - | 635.2 | - | Upgrade
|
| Investing Cash Flow | -1,257 | -1,505 | -1,324 | -982.13 | -118.21 | -668.88 | Upgrade
|
| Long-Term Debt Issued | - | 1,890 | 1,036 | - | 332.6 | 360 | Upgrade
|
| Long-Term Debt Repaid | - | -515.82 | -8.77 | -6.88 | -970 | -360 | Upgrade
|
| Net Debt Issued (Repaid) | 92.67 | 1,374 | 1,027 | -6.88 | -637.4 | - | Upgrade
|
| Issuance of Common Stock | 41.79 | 60.79 | 53.78 | 76.7 | 1,067 | - | Upgrade
|
| Common Dividends Paid | -146.96 | -110.28 | -139.52 | -137.64 | -119.7 | -94.76 | Upgrade
|
| Other Financing Activities | - | -716.49 | - | -27.73 | 5 | 418.57 | Upgrade
|
| Financing Cash Flow | -12.5 | 608.19 | 941.52 | -95.56 | 314.49 | 323.81 | Upgrade
|
| Foreign Exchange Rate Adjustments | -3.94 | 3.74 | 15.38 | -2.9 | -17.65 | 6.32 | Upgrade
|
| Net Cash Flow | -198.2 | 20.71 | -60.7 | -553.96 | 824.65 | 216.33 | Upgrade
|
| Free Cash Flow | 164.07 | -181.79 | -703.8 | -231.75 | -39.81 | -65.34 | Upgrade
|
| Free Cash Flow Margin | 6.21% | -7.40% | -29.61% | -10.32% | -2.13% | -4.21% | Upgrade
|
| Free Cash Flow Per Share | 0.39 | -0.43 | -1.69 | -0.56 | -0.10 | -0.16 | Upgrade
|
| Cash Income Tax Paid | 110.29 | 94.58 | 111.5 | 152.36 | 98.57 | 80.7 | Upgrade
|
| Levered Free Cash Flow | -8.61 | -963.4 | -121.69 | -202.98 | -208.4 | -334.07 | Upgrade
|
| Unlevered Free Cash Flow | 20.91 | -929.06 | 0.69 | -193.12 | -183.49 | -304.03 | Upgrade
|
| Change in Net Working Capital | -346.65 | 294.99 | -495.65 | -96.86 | -55.16 | 50.3 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.